 VolitionRx NYSE-A:VNRX has outlined its key achievements in 2022 as the organization transitions from a company solely focused on research and development to one with commercial operations. Henderson, Nevada-based Volition is a multi-national epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. 